Electrocardiographic criteria in founder mutations related to Arrhythmogenic cardiomyopathy
Open Access
- 1 January 2018
- journal article
- Published by Heighten Science Publications Corporation in Journal of Cardiology and Cardiovascular Medicine
- Vol. 3 (1), 006-007
- https://doi.org/10.29328/journal.jccm.1001021
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Ventricular tachycardia ablation in arrhythmogenic right ventricular cardiomyopathy patients with TMEM43 gene mutationsJournal of Cardiovascular Electrophysiology, 2017
- Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathiesHeart Rhythm, 2017
- Low amplitude of inverted T-waves in lead aVR characterise patients with arrhythmogenic cardiomyopathyInternational Journal of Cardiology, 2016
- Prognostic value of epsilon waves in lead aVR in arrhythmogenic cardiomyopathyInternational Journal of Cardiology, 2015
- Clinical importance of lead aVR in arrhythmogenic cardiomyopathyInternational Journal of Cardiology, 2014
- Outcome in Phospholamban R14del CarriersCirculation: Cardiovascular Genetics, 2014
- The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleusEuropean Heart Journal, 2014
- Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy According to Revised 2010 Task Force Criteria With Inclusion of Non-Desmosomal Phospholamban Mutation CarriersThe American Journal of Cardiology, 2013
- The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43Clinical Genetics, 2013
- Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Is a Fully Penetrant, Lethal Arrhythmic Disorder Caused by a Missense Mutation in the TMEM43 GeneAmerican Journal of Human Genetics, 2008